This is a Validated Antibody Database (VAD) review about mouse PD 1, based on 209 published articles (read how Labome selects the articles), using PD 1 antibody in all methods. It is aimed to help Labome visitors find the most suited PD 1 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
PD 1 synonym: Ly101; PD-1; Pdc1

others
 PD 1 antibody (BioLegend, 29F.1A12) was used . J Exp Med (2017) ncbi
BioLegend
rat monoclonal (29F.1A12)
  • other; mouse; loading ...
BioLegend PD 1 antibody (BioLegend, 135202) was used in other on mouse samples . Nat Commun (2021) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse
BioLegend PD 1 antibody (BioLegend, RMP1-30) was used in flow cytometry on mouse samples . Sci Adv (2021) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 2a
BioLegend PD 1 antibody (BioLegend, RMP1-30) was used in flow cytometry on mouse samples (fig 2a). Commun Biol (2021) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; 1:500; loading ...; fig 2e
BioLegend PD 1 antibody (BioLegend, 29F.1A12) was used in flow cytometry on mouse samples at 1:500 (fig 2e). Sci Adv (2021) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...
BioLegend PD 1 antibody (Biolegend, 29F.1A12) was used in flow cytometry on mouse samples . Int J Mol Sci (2021) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; fig 5j
BioLegend PD 1 antibody (Biolegend, 135210) was used in flow cytometry on mouse samples (fig 5j). J Immunother Cancer (2021) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; 1:200; loading ...
BioLegend PD 1 antibody (BioLegend, 29F.1A12) was used in flow cytometry on mouse samples at 1:200. Cancer Res (2021) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; 1:100; loading ...; fig s22a
BioLegend PD 1 antibody (Biolegend, 29F.1A12) was used in flow cytometry on mouse samples at 1:100 (fig s22a). Nat Commun (2021) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; 1:1000; loading ...; fig e6a
BioLegend PD 1 antibody (Biolegend, 109109) was used in flow cytometry on mouse samples at 1:1000 (fig e6a). Nat Cancer (2021) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; 1:200; loading ...
BioLegend PD 1 antibody (Biolegend, 29F.1A12) was used in flow cytometry on mouse samples at 1:200. Nat Commun (2021) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; 1:200; fig 1b
BioLegend PD 1 antibody (Biolegend, RMP1-30) was used in flow cytometry on mouse samples at 1:200 (fig 1b). Front Immunol (2021) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; human; loading ...
BioLegend PD 1 antibody (Biolegend, 135209) was used in flow cytometry on human samples . J Immunother Cancer (2021) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig s2d
BioLegend PD 1 antibody (Biolegend, 135220) was used in flow cytometry on mouse samples (fig s2d). Cell (2021) ncbi
rat monoclonal (29F.1A12)
  • mass cytometry; mouse; loading ...
BioLegend PD 1 antibody (BioLegend, 135202) was used in mass cytometry on mouse samples . Br J Cancer (2021) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; 1:200; loading ...
BioLegend PD 1 antibody (Biolegend, 135231) was used in flow cytometry on mouse samples at 1:200. Nature (2021) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig 3c
BioLegend PD 1 antibody (Biolegend, 135225) was used in flow cytometry on mouse samples (fig 3c). Nat Commun (2021) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; fig 1
BioLegend PD 1 antibody (BioLegend, RMP1-30) was used in flow cytometry on mouse samples (fig 1). Aging Cell (2021) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig 4b
BioLegend PD 1 antibody (BioLegend, 29F.1A12) was used in flow cytometry on mouse samples (fig 4b). Commun Biol (2020) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...
BioLegend PD 1 antibody (BioLegend, 135231) was used in flow cytometry on mouse samples . Cell (2020) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig 2s1a
BioLegend PD 1 antibody (Biolegend, 135215) was used in flow cytometry on mouse samples (fig 2s1a). elife (2020) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; 1:400; loading ...; fig 6d
BioLegend PD 1 antibody (BioLegend, 29F.1A12) was used in flow cytometry on mouse samples at 1:400 (fig 6d). J Clin Invest (2020) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 5f
BioLegend PD 1 antibody (Biolegend, RMP1-30) was used in flow cytometry on mouse samples (fig 5f). Cell (2020) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig 1k
BioLegend PD 1 antibody (BioLegend, 29F.1A12) was used in flow cytometry on mouse samples (fig 1k). Sci Adv (2020) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig s3a, s3b, s3c, s4a
BioLegend PD 1 antibody (BioLegend, 135230) was used in flow cytometry on mouse samples (fig s3a, s3b, s3c, s4a). Cancers (Basel) (2020) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig 6s1
BioLegend PD 1 antibody (Biolegend, 29F.1A12) was used in flow cytometry on mouse samples (fig 6s1). elife (2020) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; fig s4b
BioLegend PD 1 antibody (BioLegend, 29F.1A12) was used in flow cytometry on mouse samples (fig s4b). Sci Adv (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; 1:200; loading ...; fig 2s1a
BioLegend PD 1 antibody (BioLegend, 135219) was used in flow cytometry on mouse samples at 1:200 (fig 2s1a). elife (2019) ncbi
rat monoclonal (29F.1A12)
  • mass cytometry; mouse; 3 ug/ml; loading ...; fig 5d
BioLegend PD 1 antibody (Biolegend, 29F.1A12) was used in mass cytometry on mouse samples at 3 ug/ml (fig 5d). Science (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig s3e
BioLegend PD 1 antibody (BioLegend, 29F.1A12) was used in flow cytometry on mouse samples (fig s3e). Science (2019) ncbi
rat monoclonal (29F.1A12)
  • blocking or activating experiments; mouse; loading ...; fig 4a
BioLegend PD 1 antibody (BioLegend, 29F.1A12) was used in blocking or activating experiments on mouse samples (fig 4a). Nature (2019) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 2b
BioLegend PD 1 antibody (BioLegend, 109109) was used in flow cytometry on mouse samples (fig 2b). Immunity (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig 3b
BioLegend PD 1 antibody (BioLegend, 29F) was used in flow cytometry on mouse samples (fig 3b). Aging (Albany NY) (2019) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...
BioLegend PD 1 antibody (Biolegend, 109120) was used in flow cytometry on mouse samples . Cell Rep (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig 5d
BioLegend PD 1 antibody (Biolegend, 135206) was used in flow cytometry on mouse samples (fig 5d). Cell (2019) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig s4f
BioLegend PD 1 antibody (Biolegend, 109110) was used in flow cytometry on mouse samples (fig s4f). Cell (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; 1:200; loading ...; fig 3a, 3b
BioLegend PD 1 antibody (BioLegend, 135206) was used in flow cytometry on mouse samples at 1:200 (fig 3a, 3b). Nat Immunol (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; 1:100; fig 4a
BioLegend PD 1 antibody (Biolegend, 135223) was used in flow cytometry on mouse samples at 1:100 (fig 4a). Nat Commun (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig s3h
BioLegend PD 1 antibody (Biolegend, 29F.1A12) was used in flow cytometry on mouse samples (fig s3h). JCI Insight (2019) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; 1:200; loading ...; fig 2s1a
BioLegend PD 1 antibody (Biolegend, RMP1-30) was used in flow cytometry on mouse samples at 1:200 (fig 2s1a). elife (2019) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 2d
BioLegend PD 1 antibody (BioLegend, RMP1-30) was used in flow cytometry on mouse samples (fig 2d). Nature (2019) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig s1b
BioLegend PD 1 antibody (Biolegend, 109104) was used in flow cytometry on mouse samples (fig s1b). Cell Rep (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; 1:80; loading ...; fig s3a
BioLegend PD 1 antibody (Biolegend, 135208) was used in flow cytometry on mouse samples at 1:80 (fig s3a). Nat Commun (2019) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 1b
BioLegend PD 1 antibody (Biolegend, RMP1-30) was used in flow cytometry on mouse samples (fig 1b). Front Immunol (2019) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 1b
BioLegend PD 1 antibody (Biolegend, RMP1-30) was used in flow cytometry on mouse samples (fig 1b). Science (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; 1:100; loading ...; fig 2e, 5c
BioLegend PD 1 antibody (Biolegend, 135206) was used in flow cytometry on mouse samples at 1:100 (fig 2e, 5c). Nat Commun (2019) ncbi
rat monoclonal (RMP1-14)
  • flow cytometry; mouse; loading ...; fig s5l
BioLegend PD 1 antibody (Biolegend, 114118) was used in flow cytometry on mouse samples (fig s5l). Cell (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig s6e
BioLegend PD 1 antibody (BD Biosciences, 135215) was used in flow cytometry on mouse samples (fig s6e). Cell (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; 1:100; loading ...; fig 2b
BioLegend PD 1 antibody (Biolegend, 29F.1A12) was used in flow cytometry on mouse samples at 1:100 (fig 2b). Science (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig ex2b
BioLegend PD 1 antibody (Biolegend, 135221) was used in flow cytometry on mouse samples (fig ex2b). Nature (2019) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 2c
BioLegend PD 1 antibody (BioLegend, RMP1-30) was used in flow cytometry on mouse samples (fig 2c). J Exp Med (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig s8b
BioLegend PD 1 antibody (BioLegend, 135216) was used in flow cytometry on mouse samples (fig s8b). Nat Commun (2019) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig s1a
BioLegend PD 1 antibody (Biolegend, RMP1-30) was used in flow cytometry on mouse samples (fig s1a). Science (2019) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 5e
BioLegend PD 1 antibody (Biolegend, 109110) was used in flow cytometry on mouse samples (fig 5e). Cell (2019) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 3c
BioLegend PD 1 antibody (BioLegend, RMPI-30) was used in flow cytometry on mouse samples (fig 3c). J Exp Med (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; 1:400; loading ...; fig 3e
BioLegend PD 1 antibody (Biolegend, 135205) was used in flow cytometry on mouse samples at 1:400 (fig 3e). Nat Mater (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig 6c
BioLegend PD 1 antibody (BioLegend, 29F.1A12) was used in flow cytometry on mouse samples (fig 6c). J Immunol (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig 4a
BioLegend PD 1 antibody (Biolegend, 29F.1A12) was used in flow cytometry on mouse samples (fig 4a). Int J Cancer (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig e1b
BioLegend PD 1 antibody (Biolegend, 29F.1A12) was used in flow cytometry on mouse samples (fig e1b). Nature (2019) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig s2b, s2k
BioLegend PD 1 antibody (BioLegend, 29F.1A12) was used in flow cytometry on mouse samples (fig s2b, s2k). Cell Rep (2018) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig s14a
BioLegend PD 1 antibody (BioLegend, 29F.1A12) was used in flow cytometry on mouse samples (fig s14a). J Clin Invest (2019) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 2a, 3a
BioLegend PD 1 antibody (BioLegend, 109116) was used in flow cytometry on mouse samples (fig 2a, 3a). Cell (2018) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig s7d
BioLegend PD 1 antibody (Biolegend, 29F.1A12) was used in flow cytometry on mouse samples (fig s7d). Science (2018) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 6b
BioLegend PD 1 antibody (BioLegend, 109110) was used in flow cytometry on mouse samples (fig 6b). Immunity (2018) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig s1a
BioLegend PD 1 antibody (BioLegend, 135219) was used in flow cytometry on mouse samples (fig s1a). Immunity (2018) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig e4c
BioLegend PD 1 antibody (Biolegend, 29F.1A12) was used in flow cytometry on mouse samples (fig e4c). Nature (2018) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 1e
BioLegend PD 1 antibody (BioLegend, RMP1-30) was used in flow cytometry on mouse samples (fig 1e). Oncoimmunology (2018) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; 1:200; loading ...; fig 3c
BioLegend PD 1 antibody (BioLegend, RMPI.30) was used in flow cytometry on mouse samples at 1:200 (fig 3c). J Clin Invest (2018) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 3a
BioLegend PD 1 antibody (Biolegend, RMP1-30) was used in flow cytometry on mouse samples (fig 3a). Sci Rep (2018) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; fig 7b
BioLegend PD 1 antibody (BioLegend, 109103) was used in flow cytometry on mouse samples (fig 7b). Cell (2018) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 7b
BioLegend PD 1 antibody (BioLegend, RMP1-30) was used in flow cytometry on mouse samples (fig 7b). J Immunol (2018) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; fig 3e
BioLegend PD 1 antibody (Biolegend, RMP1-30) was used in flow cytometry on mouse samples (fig 3e). JCI Insight (2017) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig 4b
BioLegend PD 1 antibody (Biolegend, 29F.1A12) was used in flow cytometry on mouse samples (fig 4b). J Immunol (2018) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig 4a
BioLegend PD 1 antibody (Biolegend, 29F.1A12) was used in flow cytometry on mouse samples (fig 4a). J Exp Med (2018) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; 1:400; loading ...; fig 4a
BioLegend PD 1 antibody (BioLegend, RMP1-30) was used in flow cytometry on mouse samples at 1:400 (fig 4a). Nat Commun (2017) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 1b
BioLegend PD 1 antibody (BioLegend, RMP1-30) was used in flow cytometry on mouse samples (fig 1b). Immunology (2017) ncbi
rat monoclonal (29F.1A12)
  • flow cytometry; mouse; loading ...; fig 1a
BioLegend PD 1 antibody (Biolegend, 29F.1A12) was used in flow cytometry on mouse samples (fig 1a). Eur J Immunol (2017) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 3c
In order to find factors that regulate follicular T helper cell migration and function, BioLegend PD 1 antibody (Biolegend, RMP1-30) was used in flow cytometry on mouse samples (fig 3c). Science (2017) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; fig s8c
In order to investigate how aging affects transcriptional dynamics in naive and CD4 positive T cells, BioLegend PD 1 antibody (BioLegend, RMP1-30) was used in flow cytometry on mouse samples (fig s8c). Science (2017) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 4h
In order to examine the relationships among the B cell receptor, TLR9, and cytokine signals that regulate B cell responses to DNA-containing antigens, BioLegend PD 1 antibody (BioLegend, RMP1-30) was used in flow cytometry on mouse samples (fig 4h). J Clin Invest (2017) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig s3f
In order to investigate the use of red blood cells expressing disease-associated autoantigenas a means of inducing antigen-specific tolerance, BioLegend PD 1 antibody (BioLegend, 109110) was used in flow cytometry on mouse samples (fig s3f). Proc Natl Acad Sci U S A (2017) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 6a
In order to study the role of PD-1 and Tim-3 crosstalk in the regulation of antitumor T cell responses, BioLegend PD 1 antibody (Biolegend, 109111) was used in flow cytometry on mouse samples (fig 6a). Oncoimmunology (2016) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 3e
In order to study CD153+ PD-1+ CD44hi CD4+ T cells in the visceral adipose tissue of high fat diet-fed obese mice, BioLegend PD 1 antibody (BioLegend, RMP1-30) was used in flow cytometry on mouse samples (fig 3e). J Clin Invest (2016) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 4e
In order to study the role of TMEM16F in limiting T cell responses in mice infected with virus, BioLegend PD 1 antibody (BioLegend, 109109) was used in flow cytometry on mouse samples (fig 4e). J Exp Med (2016) ncbi
rat monoclonal (RMP1-30)
In order to test if a diet high in fats affects the development of respiratory tolerance, BioLegend PD 1 antibody (Biolenged, RMPI 1-30) was used . PLoS ONE (2016) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; fig 1a
BioLegend PD 1 antibody (BioLegend, RMP1-30) was used in flow cytometry on mouse samples (fig 1a). J Exp Med (2016) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; fig 3a
In order to assess a CD 4 T-cell population during tuberculosis that has memory-like properties maintained by Bcl6 and ICOS-dependent pathways, BioLegend PD 1 antibody (BioLegend, RMP1-30) was used in flow cytometry on mouse samples (fig 3a). J Exp Med (2015) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse
In order to investigate the role of T reg cells in exhaustion of lymphocytic choriomeningitis virus-specific CD8 T cells, BioLegend PD 1 antibody (BioLegend, RMP1-30) was used in flow cytometry on mouse samples . J Exp Med (2014) ncbi
Invitrogen
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 2i
Invitrogen PD 1 antibody (eBioscience, RMP1-30) was used in flow cytometry on mouse samples (fig 2i). Signal Transduct Target Ther (2021) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 3a
Invitrogen PD 1 antibody (eBioscience, RMP1-30) was used in flow cytometry on mouse samples (fig 3a). Proc Natl Acad Sci U S A (2021) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:100; fig 1c
Invitrogen PD 1 antibody (Thermo Fisher Scientific, 12-9985-82) was used in flow cytometry on mouse samples at 1:100 (fig 1c). elife (2021) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 1
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig 1). Aging Cell (2021) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 3b
Invitrogen PD 1 antibody (eBioscience, (CD279, clone J43)) was used in flow cytometry on mouse samples (fig 3b). elife (2020) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:200; loading ...; fig 3e
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples at 1:200 (fig 3e). elife (2020) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 6e
Invitrogen PD 1 antibody (eBioscience, 12-9985-82) was used in flow cytometry on mouse samples (fig 6e). elife (2020) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 5c
Invitrogen PD 1 antibody (Thermo Fisher, PA5-20350) was used in western blot on human samples (fig 5c). Sci Adv (2020) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; 1:100; loading ...; fig 5b
Invitrogen PD 1 antibody (eBioscience, 17998182) was used in flow cytometry on mouse samples at 1:100 (fig 5b). Nat Commun (2019) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:100; fig e8a
Invitrogen PD 1 antibody (ThermoFisher Scientific, 12-9985-82) was used in flow cytometry on mouse samples at 1:100 (fig e8a). Nature (2019) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:100; loading ...; fig 5d
Invitrogen PD 1 antibody (eBioscience, 25-9985-80) was used in flow cytometry on mouse samples at 1:100 (fig 5d). Nat Metab (2019) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 2a
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig 2a). BMC Complement Altern Med (2019) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:200; loading ...; fig 3c, 3f, s8d, s8e
Invitrogen PD 1 antibody (invitrogen, J43) was used in flow cytometry on mouse samples at 1:200 (fig 3c, 3f, s8d, s8e). Science (2019) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 1a
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig 1a). J Virol (2019) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:200; loading ...; fig 4c
Invitrogen PD 1 antibody (eBioscience, 46-9985-82) was used in flow cytometry on mouse samples at 1:200 (fig 4c). Cell Rep (2018) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 6k
Invitrogen PD 1 antibody (eBioscience, 25-9985-82) was used in flow cytometry on mouse samples (fig 6k). Cell Rep (2018) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:500; loading ...; fig 4d
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples at 1:500 (fig 4d). Nat Commun (2018) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 1h
Invitrogen PD 1 antibody (ebioscience, J43) was used in flow cytometry on mouse samples (fig 1h). Nat Commun (2018) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 4e
Invitrogen PD 1 antibody (eBioscience, RMP1-30) was used in flow cytometry on mouse samples (fig 4e). J Clin Invest (2018) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 1a
Invitrogen PD 1 antibody (eBiosciences, J43) was used in flow cytometry on mouse samples (fig 1a). Cancer Cell (2018) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 6a
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig 6a). J Immunol (2018) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 1b
Invitrogen PD 1 antibody (Thermo Fisher Scientific, 11-9985-82) was used in flow cytometry on mouse samples (fig 1b). Cell (2018) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig s3h
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig s3h). Cancer Res (2018) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:50; loading ...; fig 1b
Invitrogen PD 1 antibody (ebioscience, J43) was used in flow cytometry on mouse samples at 1:50 (fig 1b). Nat Commun (2017) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:200; loading ...; fig 1a, 1e
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples at 1:200 (fig 1a, 1e). Nat Commun (2017) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 4d
In order to investigate the involvement of achaete-scute complex homologue 2 in the pathogenesis of Sjogren's syndrome-like disease in the NOD/ShiLtJ mouse, Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig 4d). Immunol Lett (2017) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig s12c
In order to evaluate mouse models of hepacivirus infection, Invitrogen PD 1 antibody (eBioscience, RMP1-30) was used in flow cytometry on mouse samples (fig s12c). Science (2017) ncbi
hamsters monoclonal (J43)
  • immunohistochemistry; mouse; loading ...; fig 1b
In order to investigate the effect of PD-1 expression on phagocytosis and tumour immunity, Invitrogen PD 1 antibody (eBioscience, J43) was used in immunohistochemistry on mouse samples (fig 1b). Nature (2017) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 4a
In order to generate and characterize Treg-of-B cells, Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig 4a). Sci Rep (2017) ncbi
mouse monoclonal (7A11B1)
  • immunohistochemistry - paraffin section; rat; loading ...; fig 4f
  • immunoprecipitation; rat; loading ...; fig 2b
  • immunocytochemistry; rat; loading ...; fig 5b
  • western blot; rat; loading ...; fig 3b
In order to assess the critical role of programmed death protein 1/programmed death-ligand 1 in the polarization of microglia during intracerebral hemorrhage-induced secondary brain injury, Invitrogen PD 1 antibody (Thermo Fisher, MA5-15780) was used in immunohistochemistry - paraffin section on rat samples (fig 4f), in immunoprecipitation on rat samples (fig 2b), in immunocytochemistry on rat samples (fig 5b) and in western blot on rat samples (fig 3b). J Neuroinflammation (2017) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:200; loading ...; fig 3g
In order to evaluate the use of a recombinant Newcastle disease virus expressing ICOS ligand to treat cancer, Invitrogen PD 1 antibody (eBioscience, 25-9985) was used in flow cytometry on mouse samples at 1:200 (fig 3g). Nat Commun (2017) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 2c
Invitrogen PD 1 antibody (eBioscience, RMP1-30) was used in flow cytometry on mouse samples (fig 2c). Blood (2017) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 6b
In order to evaluate miR-29a in B cells as a potential therapeutic target in arthritis, Invitrogen PD 1 antibody (eBiosciences, J43) was used in flow cytometry on mouse samples (fig 6b). Cell Mol Life Sci (2017) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig s2
In order to analyze the in vivo effect of atorvastatin on regulatory T cells and its association with the inflammatory process in a model of allergic asthma, Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig s2). Front Immunol (2016) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 7
In order to examine natural killer T cell development in mice deficient for SLAM family receptors, Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig 7). J Exp Med (2017) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; 1:400; loading ...; fig 3a
In order to test how inhibiting autophagy impacts antitumor immune responses in immune-competent mouse models of melanoma and mammary cancer, Invitrogen PD 1 antibody (eBioscience, RMP1-30) was used in flow cytometry on mouse samples at 1:400 (fig 3a). J Clin Invest (2016) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 2d
In order to discuss how Th1-driven inflammation affects Treg homeostasis in atherosclerosis, Invitrogen PD 1 antibody (eBioscience, RMP1-30) was used in flow cytometry on mouse samples (fig 2d). Circ Res (2016) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 2a
In order to explore the role of exhausted CD8 positive CXCR5 positive T cells in mice chronically infected with lymphocytic choriomeningitis virus, Invitrogen PD 1 antibody (eBioscience, RMP1-30) was used in flow cytometry on mouse samples (fig 2a). Nature (2016) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; human; 1:200; fig 1
  • flow cytometry; mouse; 1:200; fig 1
Invitrogen PD 1 antibody (eBiosciences, 17-9981-82) was used in flow cytometry on human samples at 1:200 (fig 1) and in flow cytometry on mouse samples at 1:200 (fig 1). Nat Commun (2016) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 4b
In order to assess how ABCG1 loss in T cells affects atherosclerosis, Invitrogen PD 1 antibody (eBioscience, RMP1-30) was used in flow cytometry on mouse samples (fig 4b). J Clin Invest (2016) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 5f
In order to analyze the effects of beta-lactam-plus-macrolide therapy using a lethal pneumococcal pneumonia mouse infection model, Invitrogen PD 1 antibody (eBiosciences, J43) was used in flow cytometry on mouse samples (fig 5f). Antimicrob Agents Chemother (2016) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 5
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig 5). Clin Cancer Res (2017) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 3g
In order to identify a B cell-intrinsic mechanism by which IFN signaling promotes lupus pathogenesis, Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig 3g). J Exp Med (2016) ncbi
hamsters monoclonal (J43)
  • western blot; mouse; fig 6
Invitrogen PD 1 antibody (eBioscience, J43) was used in western blot on mouse samples (fig 6). Cell Death Dis (2016) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 1b
In order to report that the majority of microbe-specific naive T cells produced memory cells during infection, Invitrogen PD 1 antibody (eBiosciences, J43) was used in flow cytometry on mouse samples (fig 1b). Science (2016) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:200; fig 1
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples at 1:200 (fig 1). Nat Commun (2016) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 3a
In order to test if T regulatory cells from mice lacking both DEF-6 and SWAP-70 have an increased capacity to become effector T regulatory cells due to altered IRF-4 activity, Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig 3a). Arthritis Rheumatol (2016) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:100; fig 4, 7
In order to assess how IL-7 signaling represses TFH and Bcl-6, Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples at 1:100 (fig 4, 7). Nat Commun (2016) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 4
In order to study apolipoprotein-1 during normocholesterolemic conditions, Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig 4). J Immunol (2015) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 2f
In order to determine the mechanism by which BCR-ABL positive leukemia escapes immune surveillance, Invitrogen PD 1 antibody (eBiosciences, J43) was used in flow cytometry on mouse samples (fig 2f). J Immunol (2015) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; fig 3
Invitrogen PD 1 antibody (eBioscience, RMPI-30) was used in flow cytometry on mouse samples (fig 3). Oncotarget (2015) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 2
Invitrogen PD 1 antibody (eBiosciences, J43) was used in flow cytometry on mouse samples (fig 2). Nat Immunol (2015) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 1e
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig 1e). Cancer Res (2015) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; tbl s1
In order to study the role of ICOS in group 2 innate lymphoid cell responses, Invitrogen PD 1 antibody (eBiosciences, RMP1-30) was used in flow cytometry on mouse samples (tbl s1). Biochem Biophys Res Commun (2015) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; loading ...; fig 3A
In order to explore the roles of T and B cells in chronic graft-versus-host disease, Invitrogen PD 1 antibody (eBioscience, RMP1-30) was used in flow cytometry on mouse samples (fig 3A). Ann Hematol (2015) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; 1:100; fig s2
Invitrogen PD 1 antibody (eBioscience, RMP1-30) was used in flow cytometry on mouse samples at 1:100 (fig s2). Nat Commun (2015) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; fig 2
Invitrogen PD 1 antibody (eBioscience, 12-9981) was used in flow cytometry on mouse samples (fig 2). EMBO Mol Med (2015) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig s2
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig s2). PLoS ONE (2015) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 2b
In order to test if blocking several checkpoint receptors boosts anti-tumor immunity in a low-dose, lymphodepleting whole body radiation model, Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig 2b). J Immunother Cancer (2015) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 6
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig 6). PLoS Pathog (2015) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 3
In order to show that the PTEN-mTORC2 axis maintains T regulatory cell stability and coordinates their control of effector responses, Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig 3). Nat Immunol (2015) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples . Immunol Lett (2015) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 2
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples (fig 2). J Immunol (2015) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; fig 5b
In order to test the efficacy of combining different monoclonal antibodies to treat cancer, Invitrogen PD 1 antibody (ebioscience, 14-9981-82) was used in flow cytometry on mouse samples (fig 5b). Clin Cancer Res (2015) ncbi
hamsters monoclonal (J43)
  • flow cytometry; human
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on human samples . Cancer Res (2014) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse
In order to study Bacillus Calmette-Guerin DeltaureC::hly and the superior protection against tuberculosis caused by central memory CD4+ T cells, Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples . J Infect Dis (2014) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:100; loading ...; fig 2a
In order to study the role of FoxP3 positive regulatory T cells in controlling T follicular helper and germinal center B-cell responses to influenza, Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples at 1:100 (fig 2a). Nat Commun (2014) ncbi
rat monoclonal (RMP1-30)
  • flow cytometry; mouse; fig 4
In order to examine the contribution of PD-L1 or PD-L2 to limiting stroke severity, Invitrogen PD 1 antibody (eBioscience, RMP1-30) was used in flow cytometry on mouse samples (fig 4). J Neuroinflammation (2013) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 3
Invitrogen PD 1 antibody (Ebioscience, J43) was used in flow cytometry on mouse samples (fig 3). PLoS Pathog (2013) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse
Invitrogen PD 1 antibody (eBioscience, J43) was used in flow cytometry on mouse samples . J Immunol (2011) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 1
Invitrogen PD 1 antibody (eBiosciences, J43) was used in flow cytometry on mouse samples (fig 1). PLoS ONE (2011) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 1
In order to characterize and compare T helper 1 and 17 cells, Invitrogen PD 1 antibody (eBiosciences, J43) was used in flow cytometry on mouse samples (fig 1). J Leukoc Biol (2007) ncbi
hamsters monoclonal (J43)
  • blocking or activating experiments; mouse
In order to investigate the roles of PD-L1 and PD-L2 expressed by dendritic cells in naive CD4+ T cell activation, Invitrogen PD 1 antibody (eBioscience, J43) was used in blocking or activating experiments on mouse samples . Eur J Immunol (2006) ncbi
hamsters monoclonal (J43)
  • blocking or activating experiments; mouse; 10 ug/ml
  • flow cytometry; mouse
Invitrogen PD 1 antibody (eBioscience, J43) was used in blocking or activating experiments on mouse samples at 10 ug/ml and in flow cytometry on mouse samples . Nephrol Dial Transplant (2004) ncbi
Bio X Cell
rat monoclonal (RMP1-14)
  • blocking or activating experiments; mouse; fig 6a
Bio X Cell PD 1 antibody (BioXCell, RMP1-14) was used in blocking or activating experiments on mouse samples (fig 6a). J Immunother Cancer (2021) ncbi
rat monoclonal (RMP1-14)
  • blocking or activating experiments; mouse; ; fig 6f
Bio X Cell PD 1 antibody (InVivoMab, RMP1-14) was used in blocking or activating experiments on mouse samples at (fig 6f). Nat Commun (2021) ncbi
rat monoclonal (29F.1A12)
  • blocking or activating experiments; mouse; ; fig 5i
Bio X Cell PD 1 antibody (BioXcell, 29 F.1A12) was used in blocking or activating experiments on mouse samples at (fig 5i). J Immunother Cancer (2021) ncbi
rat monoclonal (RMP1-14)
  • blocking or activating experiments; mouse; ; fig s2a
Bio X Cell PD 1 antibody (BioXCell, RMP1-14) was used in blocking or activating experiments on mouse samples at (fig s2a). Nat Commun (2021) ncbi
rat monoclonal (29F.1A12)
  • other; mouse
Bio X Cell PD 1 antibody (BioXcell, 29F.1A12) was used in other on mouse samples . Nat Commun (2020) ncbi
rat monoclonal (29F.1A12)
  • blocking or activating experiments; mouse; ; fig 6c
Bio X Cell PD 1 antibody (BioXcell, 29F.1A12) was used in blocking or activating experiments on mouse samples at (fig 6c). Nat Commun (2020) ncbi
hamsters monoclonal (J43)
  • blocking or activating experiments; mouse; ; fig 8b
Bio X Cell PD 1 antibody (BioXcell, J43) was used in blocking or activating experiments on mouse samples at (fig 8b). Nat Commun (2020) ncbi
rat monoclonal (RMP1-14)
  • blocking or activating experiments; mouse; fig 7b
Bio X Cell PD 1 antibody (Bio X Cell, RMP1-14) was used in blocking or activating experiments on mouse samples (fig 7b). Aging (Albany NY) (2020) ncbi
rat monoclonal (RMP1-14)
  • immunohistochemistry; mouse; fig s5
Bio X Cell PD 1 antibody (BioXcell, RMP 1-C14) was used in immunohistochemistry on mouse samples (fig s5). BMC Genomics (2020) ncbi
rat monoclonal (RMP1-14)
  • blocking or activating experiments; mouse; ; fig 1f
Bio X Cell PD 1 antibody (Bio X cell, RMP1-14) was used in blocking or activating experiments on mouse samples at (fig 1f). Science (2019) ncbi
hamsters monoclonal (J43)
  • other; mouse; 200 ug/mouse; loading ...; fig 1B
In order to assess whether programmed cell death 1 regulates psoriasiform dermatitis in mice, Bio X Cell PD 1 antibody (Bio X Cell, J43) was used in other on mouse samples at 200 ug/mouse (fig 1B). J Immunol (2015) ncbi
Abcam
mouse monoclonal (NAT105)
  • immunohistochemistry; human; 1:400; loading ...; fig s2a
Abcam PD 1 antibody (Abcam, NAT105) was used in immunohistochemistry on human samples at 1:400 (fig s2a). Neuropathol Appl Neurobiol (2021) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; loading ...
Abcam PD 1 antibody (Abcam, ab52587) was used in immunohistochemistry - paraffin section on human samples . elife (2020) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 4d
Abcam PD 1 antibody (Abcam, ab52587) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 4d). Front Immunol (2019) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; loading ...; fig 1b
Abcam PD 1 antibody (Abcam, NAT105) was used in immunohistochemistry - paraffin section on human samples (fig 1b). J Exp Med (2019) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; loading ...; fig 2
Abcam PD 1 antibody (Abcam, AB52587) was used in immunohistochemistry - paraffin section on human samples (fig 2). J Clin Invest (2019) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; loading ...; fig 2c
In order to investigate the immune composition of tumor microenvironment in hepatocellular carcinoma, Abcam PD 1 antibody (Abcam, NAT105) was used in immunohistochemistry - paraffin section on human samples (fig 2c). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry; human; loading ...; fig 5a
Abcam PD 1 antibody (Abcam, NAT105) was used in immunohistochemistry on human samples (fig 5a). Oncoimmunology (2017) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 4a
Abcam PD 1 antibody (Abcam, ab52587) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 4a). J Immunol Res (2016) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry; mouse; 1:2000; fig 5j
Abcam PD 1 antibody (Abcam, ab52587) was used in immunohistochemistry on mouse samples at 1:2000 (fig 5j). Nat Commun (2016) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; 1:100; fig 3
Abcam PD 1 antibody (Abcam, NAT105) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 3). Mod Pathol (2016) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 2c
Abcam PD 1 antibody (AbCam, ab52587) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 2c). Oncoimmunology (2015) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; 1:50; loading ...; fig 1b
Abcam PD 1 antibody (Abcam, 52587) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 1b). PLoS ONE (2015) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; 1:50
Abcam PD 1 antibody (Abcam, ab52587) was used in immunohistochemistry - paraffin section on human samples at 1:50. Blood Cancer J (2015) ncbi
mouse monoclonal (NAT105)
  • western blot; human; 1:1000; fig 4
Abcam PD 1 antibody (Abcam, ab52587) was used in western blot on human samples at 1:1000 (fig 4). Mol Med Rep (2015) ncbi
Cell Signaling Technology
domestic rabbit monoclonal (D7D5W)
  • immunohistochemistry - paraffin section; mouse; fig 6c
  • flow cytometry; mouse; loading ...; fig 2e
Cell Signaling Technology PD 1 antibody (CST, 84651S) was used in immunohistochemistry - paraffin section on mouse samples (fig 6c) and in flow cytometry on mouse samples (fig 2e). iScience (2021) ncbi
domestic rabbit monoclonal (D7D5W)
  • immunohistochemistry; mouse; fig 3e
Cell Signaling Technology PD 1 antibody (Cell Signaling Technology, D7D5W) was used in immunohistochemistry on mouse samples (fig 3e). Nat Commun (2020) ncbi
domestic rabbit monoclonal (D7D5W)
  • immunohistochemistry; mouse; 1:800; loading ...; fig 6b
Cell Signaling Technology PD 1 antibody (Cell Signaling, 84651) was used in immunohistochemistry on mouse samples at 1:800 (fig 6b). Nat Commun (2020) ncbi
domestic rabbit monoclonal (D7D5W)
  • immunohistochemistry - paraffin section; mouse; 1:50; loading ...; fig 5f
Cell Signaling Technology PD 1 antibody (Cell Signaling, 84651) was used in immunohistochemistry - paraffin section on mouse samples at 1:50 (fig 5f). Nat Metab (2019) ncbi
domestic rabbit monoclonal (D7D5W)
  • immunohistochemistry; mouse; loading ...; fig 2s
Cell Signaling Technology PD 1 antibody (Cell Signaling, D7DSW) was used in immunohistochemistry on mouse samples (fig 2s). J Immunol (2019) ncbi
BD Biosciences
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 5a
BD Biosciences PD 1 antibody (BD Biosciences, J43) was used in flow cytometry on mouse samples (fig 5a). J Immunother Cancer (2021) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse
BD Biosciences PD 1 antibody (BD, 562584) was used in flow cytometry on mouse samples . Theranostics (2021) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...
BD Biosciences PD 1 antibody (BD Pharmingen, 562671) was used in flow cytometry on mouse samples . Signal Transduct Target Ther (2021) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 2b
BD Biosciences PD 1 antibody (BD Biosciences, J43) was used in flow cytometry on mouse samples (fig 2b). Blood Adv (2020) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:400; loading ...; fig 3f
BD Biosciences PD 1 antibody (BD, J43) was used in flow cytometry on mouse samples at 1:400 (fig 3f). Nat Med (2019) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 2d
BD Biosciences PD 1 antibody (BD Biosciences, J43) was used in flow cytometry on mouse samples (fig 2d). Circulation (2018) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 6e
BD Biosciences PD 1 antibody (BD, 562671) was used in flow cytometry on mouse samples (fig 6e). Nat Commun (2018) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 3
In order to investigate the regulated egress of T-cell subsets from tumors, BD Biosciences PD 1 antibody (BD Bioscience, J43) was used in flow cytometry on mouse samples (fig 3). Proc Natl Acad Sci U S A (2017) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig s7c
In order to study the role of moesin during the generation of TGF-beta-induced T regulatory cells, BD Biosciences PD 1 antibody (BD Pharmingen, J43) was used in flow cytometry on mouse samples (fig s7c). J Clin Invest (2017) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 2b
In order to assess whether human T-cell leukemia virus type 1 bZIP factor enhances the proliferation of expressing T cells after stimulation via the T-cell receptor, BD Biosciences PD 1 antibody (BD Pharmingen, J43) was used in flow cytometry on mouse samples (fig 2b). PLoS Pathog (2017) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:100; loading ...; fig 2c
BD Biosciences PD 1 antibody (BD Biosciences, J43) was used in flow cytometry on mouse samples at 1:100 (fig 2c). Proc Natl Acad Sci U S A (2016) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:200; loading ...; tbl s2
In order to identify and characterize follicular cytotoxic T cells, BD Biosciences PD 1 antibody (BD, J43) was used in flow cytometry on mouse samples at 1:200 (tbl s2). Nat Immunol (2016) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 1
In order to report the effects of PD-L1 modulation of T cell function in graft-versus-host disease, BD Biosciences PD 1 antibody (BD Bioscience, J43) was used in flow cytometry on mouse samples (fig 1). J Clin Invest (2016) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 1, 2
In order to evaluate alleviation from psoriatic inflammation by programmed cell death ligand 1 and suppression of IL-17A production from programmed cell death 1-high T cells, BD Biosciences PD 1 antibody (BD Biosciences, J43) was used in flow cytometry on mouse samples (fig 1, 2). J Allergy Clin Immunol (2016) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 4, 5
BD Biosciences PD 1 antibody (BD Bioscience, J43) was used in flow cytometry on mouse samples (fig 4, 5). PLoS Pathog (2016) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; loading ...; fig 1G
In order to determine that Th2 cell responses, alternative macrophage activation, and immunoglobulin class switching to IgG1, are enhanced in Batf3(-/-) mice responding to helminth parasites, BD Biosciences PD 1 antibody (BD, J43) was used in flow cytometry on mouse samples (fig 1G). J Exp Med (2016) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse
BD Biosciences PD 1 antibody (BD Pharmingen, J43) was used in flow cytometry on mouse samples . J Immunol (2015) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:400; fig s3
BD Biosciences PD 1 antibody (BD, 562584) was used in flow cytometry on mouse samples at 1:400 (fig s3). Nat Commun (2015) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; 1:100; fig 1
BD Biosciences PD 1 antibody (BD Pharmingen, J43) was used in flow cytometry on mouse samples at 1:100 (fig 1). Nat Commun (2015) ncbi
hamsters monoclonal (J43)
  • flow cytometry; mouse; fig 3
In order to analyze deubiquitinization Usp9X and its regulation of proximal T cell receptor signaling and tolerance induction, BD Biosciences PD 1 antibody (BD, J43) was used in flow cytometry on mouse samples (fig 3). J Exp Med (2014) ncbi
hamsters monoclonal (J43)
  • blocking or activating experiments; mouse
BD Biosciences PD 1 antibody (BD Pharmingen, #551891) was used in blocking or activating experiments on mouse samples . Cancer Res (2014) ncbi
Articles Reviewed
  1. Zhu Y, Elsheikha H, Wang J, Fang S, He J, Zhu X, et al. Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors. J Immunother Cancer. 2021;9: pubmed publisher
  2. Zhang M, Pan X, Fujiwara K, Jurcak N, Muth S, Zhou J, et al. Pancreatic cancer cells render tumor-associated macrophages metabolically reprogrammed by a GARP and DNA methylation-mediated mechanism. Signal Transduct Target Ther. 2021;6:366 pubmed publisher
  3. Van Maldegem F, Valand K, Cole M, Patel H, Angelova M, Rana S, et al. Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. Nat Commun. 2021;12:5906 pubmed publisher
  4. Horiuchi S, Wu H, Liu W, Schmitt N, Provot J, Liu Y, et al. Tox2 is required for the maintenance of GC TFH cells and the generation of memory TFH cells. Sci Adv. 2021;7:eabj1249 pubmed publisher
  5. Susukida T, Kuwahara S, Song B, Kazaoka A, Aoki S, Ito K. Regulation of the immune tolerance system determines the susceptibility to HLA-mediated abacavir-induced skin toxicity. Commun Biol. 2021;4:1137 pubmed publisher
  6. Jiang Y, Yuan Y, Chen M, Li S, Bai J, Zhang Y, et al. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression. Theranostics. 2021;11:9162-9176 pubmed publisher
  7. Yang M, Long D, Hu L, Zhao Z, Li Q, Guo Y, et al. AIM2 deficiency in B cells ameliorates systemic lupus erythematosus by regulating Blimp-1-Bcl-6 axis-mediated B-cell differentiation. Signal Transduct Target Ther. 2021;6:341 pubmed publisher
  8. Rizvi Z, Dalal R, Sadhu S, Kumar Y, Kumar S, Gupta S, et al. High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity. Sci Adv. 2021;7:eabg5016 pubmed publisher
  9. Neumann S, Campbell K, Woodall M, Evans M, Clarkson A, Young S. Obesity Has a Systemic Effect on Immune Cells in Naïve and Cancer-Bearing Mice. Int J Mol Sci. 2021;22: pubmed publisher
  10. Lu C, Liu Z, Klement J, Yang D, Merting A, Poschel D, et al. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape. J Immunother Cancer. 2021;9: pubmed publisher
  11. Wu S, Xiao Y, Wei J, Xu X, Jin X, Hu X, et al. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. J Immunother Cancer. 2021;9: pubmed publisher
  12. Van De Velde L, Allen E, Crawford J, Wilson T, Guy C, Russier M, et al. Neuroblastoma Formation Requires Unconventional CD4 T Cells and Arginase-1-Dependent Myeloid Cells. Cancer Res. 2021;81:5047-5059 pubmed publisher
  13. Steele L, Mannion A, Shaw G, MacLennan K, Cook G, Rudd C, et al. Non-redundant activity of GSK-3α and GSK-3β in T cell-mediated tumor rejection. iScience. 2021;24:102555 pubmed publisher
  14. Ho D, Tsui Y, Chan L, Sze K, Zhang X, Cheu J, et al. Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. Nat Commun. 2021;12:3684 pubmed publisher
  15. Uyanik B, Goloudina A, Akbarali A, Grigorash B, Petukhov A, Singhal S, et al. Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses. Nat Commun. 2021;12:3622 pubmed publisher
  16. Wu Q, Tian A, Li B, Leduc M, Forveille S, Hamley P, et al. IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms. J Immunother Cancer. 2021;9: pubmed publisher
  17. Wu S, Fukumoto T, Lin J, Nacarelli T, Wang Y, Ong D, et al. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nat Cancer. 2021;2:189-200 pubmed publisher
  18. Totten S, Im Y, Cepeda Cañedo E, Najyb O, Nguyen A, Hebert S, et al. STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. Nat Commun. 2021;12:3299 pubmed publisher
  19. Zimmer T, Broekaart D, Luinenburg M, Mijnsbergen C, Anink J, Sim N, et al. Balloon cells promote immune system activation in focal cortical dysplasia type 2b. Neuropathol Appl Neurobiol. 2021;47:826-839 pubmed publisher
  20. Amoozgar Z, Kloepper J, Ren J, Tay R, Kazer S, Kiner E, et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun. 2021;12:2582 pubmed publisher
  21. Zhang S, Li L, Xie D, Reddy S, Sleasman J, Ma L, et al. Regulation of Intrinsic and Bystander T Follicular Helper Cell Differentiation and Autoimmunity by Tsc1. Front Immunol. 2021;12:620437 pubmed publisher
  22. Lin X, Twelkmeyer T, Zhu D, Zhang L, Zhao Y, Zhang C, et al. Homeostatic regulation of T follicular helper and antibody response to particle antigens by IL-1Ra of medullary sinus macrophage origin. Proc Natl Acad Sci U S A. 2021;118: pubmed publisher
  23. Zhou J, Pei X, Yang Y, Wang Z, Gao W, Ye R, et al. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma. J Immunother Cancer. 2021;9: pubmed publisher
  24. Gangoso E, Southgate B, Bradley L, Rus S, Gálvez Cancino F, McGivern N, et al. Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion. Cell. 2021;184:2454-2470.e26 pubmed publisher
  25. Joseph R, Soundararajan R, Vasaikar S, Yang F, Allton K, Tian L, et al. CD8+ T cells inhibit metastasis and CXCL4 regulates its function. Br J Cancer. 2021;125:176-189 pubmed publisher
  26. Sun Z, Yao Y, You M, Liu J, Guo W, Qi Z, et al. The kinase PDK1 is critical for promoting T follicular helper cell differentiation. elife. 2021;10: pubmed publisher
  27. Merkenschlager J, Finkin S, Ramos V, Kraft J, Cipolla M, Nowosad C, et al. Dynamic regulation of TFH selection during the germinal centre reaction. Nature. 2021;591:458-463 pubmed publisher
  28. Yang Y, Li X, Ma Z, Wang C, Yang Q, Byrne Steele M, et al. CTLA-4 expression by B-1a B cells is essential for immune tolerance. Nat Commun. 2021;12:525 pubmed publisher
  29. Webb L, Fra Bido S, Innocentin S, Matheson L, Attaf N, Bignon A, et al. Ageing promotes early T follicular helper cell differentiation by modulating expression of RBPJ. Aging Cell. 2021;20:e13295 pubmed publisher
  30. Tanaka R, Ichimura Y, Kubota N, Saito A, Nakamura Y, Ishitsuka Y, et al. Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6. Commun Biol. 2020;3:571 pubmed publisher
  31. Li Z, Zhang H, Huang Y, Huang J, Sun P, Zhou N, et al. Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. Nat Commun. 2020;11:3806 pubmed publisher
  32. Pasciuto E, Burton O, Roca C, Lagou V, Rajan W, Theys T, et al. Microglia Require CD4 T Cells to Complete the Fetal-to-Adult Transition. Cell. 2020;182:625-640.e24 pubmed publisher
  33. Peligero Cruz C, Givony T, Sebé Pedrós A, Dobes J, Kadouri N, Nevo S, et al. IL18 signaling promotes homing of mature Tregs into the thymus. elife. 2020;9: pubmed publisher
  34. Cao W, Fang F, Gould T, Li X, Kim C, Gustafson C, et al. Ecto-NTPDase CD39 is a negative checkpoint that inhibits follicular helper cell generation. J Clin Invest. 2020;130:3422-3436 pubmed publisher
  35. Gryzik S, Hoang Y, Lischke T, Mohr E, Venzke M, Kadner I, et al. Identification of a super-functional Tfh-like subpopulation in murine lupus by pattern perception. elife. 2020;9: pubmed publisher
  36. Liu X, Kong W, Peterson C, McGrail D, Hoang A, Zhang X, et al. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun. 2020;11:2135 pubmed publisher
  37. Ruscetti M, Morris J, Mezzadra R, Russell J, Leibold J, Romesser P, et al. Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell. 2020;181:424-441.e21 pubmed publisher
  38. Stebegg M, Bignon A, Hill D, Silva Cayetano A, Krueger C, Vanderleyden I, et al. Rejuvenating conventional dendritic cells and T follicular helper cell formation after vaccination. elife. 2020;9: pubmed publisher
  39. von Roemeling C, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, et al. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun. 2020;11:1508 pubmed publisher
  40. Witalis M, Chang J, Zhong M, Bouklouch Y, Panneton V, Li J, et al. Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk. Blood Adv. 2020;4:868-879 pubmed publisher
  41. Hajaj E, Eisenberg G, Klein S, Frankenburg S, Merims S, Ben David I, et al. SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint. elife. 2020;9: pubmed publisher
  42. Tezera L, Bielecka M, Ogongo P, Walker N, Ellis M, Garay Baquero D, et al. Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. elife. 2020;9: pubmed publisher
  43. Marasco M, Berteotti A, Weyershaeuser J, Thorausch N, Sikorska J, Krausze J, et al. Molecular mechanism of SHP2 activation by PD-1 stimulation. Sci Adv. 2020;6:eaay4458 pubmed publisher
  44. Chen H, Cong X, Wu C, Wu X, Wang J, Mao K, et al. Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9+ T cells. Sci Adv. 2020;6:eaax4690 pubmed publisher
  45. Cohen G, Chandran P, Lorsung R, Tomlinson L, Sundby M, Burks S, et al. The Impact of Focused Ultrasound in Two Tumor Models: Temporal Alterations in the Natural History on Tumor Microenvironment and Immune Cell Response. Cancers (Basel). 2020;12: pubmed publisher
  46. Bell L, Lenhart A, Rosenwald A, Monoranu C, Berberich Siebelt F. Lymphoid Aggregates in the CNS of Progressive Multiple Sclerosis Patients Lack Regulatory T Cells. Front Immunol. 2019;10:3090 pubmed publisher
  47. Terashima Y, Toda E, Itakura M, Otsuji M, Yoshinaga S, Okumura K, et al. Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties. Nat Commun. 2020;11:609 pubmed publisher
  48. Canel M, Taggart D, Sims A, Lonergan D, Waizenegger I, Serrels A. T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity. elife. 2020;9: pubmed publisher
  49. Sun G, Cao Y, Qian C, Wan Z, Zhu J, Guo J, et al. Romo1 is involved in the immune response of glioblastoma by regulating the function of macrophages. Aging (Albany NY). 2020;12:1114-1127 pubmed publisher
  50. Zhong W, Myers J, Wang F, Wang K, Lucas J, Rosfjord E, et al. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors. BMC Genomics. 2020;21:2 pubmed publisher
  51. Williford J, Ishihara J, Ishihara A, Mansurov A, Hosseinchi P, Marchell T, et al. Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy. Sci Adv. 2019;5:eaay1357 pubmed publisher
  52. Jimeno R, Lebrusant Fernandez M, Margreitter C, LUCAS B, Veerapen N, Kelly G, et al. Tissue-specific shaping of the TCR repertoire and antigen specificity of iNKT cells. elife. 2019;8: pubmed publisher
  53. Guo C, Allen B, Hiam K, Dodd D, Van Treuren W, Higginbottom S, et al. Depletion of microbiome-derived molecules in the host using Clostridium genetics. Science. 2019;366: pubmed publisher
  54. Shi L, Wang J, Ding N, Zhang Y, Zhu Y, Dong S, et al. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun. 2019;10:5421 pubmed publisher
  55. Leone R, Zhao L, Englert J, Sun I, Oh M, Sun I, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019;366:1013-1021 pubmed publisher
  56. Canon J, Rex K, Saiki A, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217-223 pubmed publisher
  57. Alspach E, Lussier D, Miceli A, Kizhvatov I, DuPage M, Luoma A, et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature. 2019;574:696-701 pubmed publisher
  58. Chen Z, Ji Z, Ngiow S, Manne S, Cai Z, Huang A, et al. TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision. Immunity. 2019;51:840-855.e5 pubmed publisher
  59. Shikama Y, Kurosawa M, Furukawa M, Ishimaru N, Matsushita K. Involvement of adiponectin in age-related increases in tear production in mice. Aging (Albany NY). 2019;11:8329-8346 pubmed publisher
  60. Ortega Molina A, Deleyto Seldas N, Carreras J, Sanz A, Lebrero Fernández C, Menéndez C, et al. Oncogenic Rag GTPase signaling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR. Nat Metab. 2019;1:775-789 pubmed publisher
  61. Nelson C, Thompson E, Quarnstrom C, Fraser K, Seelig D, Bhela S, et al. Robust Iterative Stimulation with Self-Antigens Overcomes CD8+ T Cell Tolerance to Self- and Tumor Antigens. Cell Rep. 2019;28:3092-3104.e5 pubmed publisher
  62. Dong M, Wang G, Chow R, Ye L, Zhu L, Dai X, et al. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. Cell. 2019;178:1189-1204.e23 pubmed publisher
  63. Benci J, Johnson L, Choa R, Xu Y, Qiu J, Zhou Z, et al. Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell. 2019;178:933-948.e14 pubmed publisher
  64. Verma V, Shrimali R, Ahmad S, Dai W, Wang H, Lu S, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019;20:1231-1243 pubmed publisher
  65. Leclerc M, Voilin E, Gros G, Corgnac S, de Montpreville V, Validire P, et al. Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. Nat Commun. 2019;10:3345 pubmed publisher
  66. Wirsching H, Zhang H, Szulzewsky F, Arora S, Grandi P, Cimino P, et al. Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. JCI Insight. 2019;4: pubmed publisher
  67. Pan X, Ma B, You X, Chen S, Wu J, Wang T, et al. Synthesized natural peptides from amphibian skin secretions increase the efficacy of a therapeutic vaccine by recruiting more T cells to the tumour site. BMC Complement Altern Med. 2019;19:163 pubmed publisher
  68. Koike T, Harada K, Horiuchi S, Kitamura D. The quantity of CD40 signaling determines the differentiation of B cells into functionally distinct memory cell subsets. elife. 2019;8: pubmed publisher
  69. Ansaldo E, Slayden L, Ching K, Koch M, Wolf N, Plichta D, et al. Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis. Science. 2019;364:1179-1184 pubmed publisher
  70. Khan O, Giles J, McDonald S, Manne S, Ngiow S, Patel K, et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature. 2019;: pubmed publisher
  71. Celis Gutierrez J, Blattmann P, Zhai Y, Jarmuzynski N, Ruminski K, Gregoire C, et al. Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. Cell Rep. 2019;27:3315-3330.e7 pubmed publisher
  72. Pascual García M, Bonfill Teixidor E, Planas Rigol E, Rubio Perez C, Iurlaro R, Arias A, et al. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy. Nat Commun. 2019;10:2416 pubmed publisher
  73. Mizuno R, Sugiura D, Shimizu K, Maruhashi T, Watada M, Okazaki I, et al. PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation. Front Immunol. 2019;10:630 pubmed publisher
  74. Sugiura D, Maruhashi T, Okazaki I, Shimizu K, Maeda T, Takemoto T, et al. Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science. 2019;364:558-566 pubmed publisher
  75. LaFleur M, Nguyen T, Coxe M, Yates K, Trombley J, Weiss S, et al. A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system. Nat Commun. 2019;10:1668 pubmed publisher
  76. Hammerich L, Marron T, Upadhyay R, Svensson Arvelund J, Dhainaut M, Hussein S, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25:814-824 pubmed publisher
  77. Binnewies M, Mujal A, Pollack J, Combes A, Hardison E, Barry K, et al. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. Cell. 2019;177:556-571.e16 pubmed publisher
  78. Poggio M, Hu T, Pai C, Chu B, BELAIR C, Chang A, et al. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell. 2019;177:414-427.e13 pubmed publisher
  79. Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019;: pubmed publisher
  80. Grootjans J, Krupka N, Hosomi S, Matute J, Hanley T, Saveljeva S, et al. Epithelial endoplasmic reticulum stress orchestrates a protective IgA response. Science. 2019;363:993-998 pubmed publisher
  81. Chen J, López Moyado I, Seo H, Lio C, Hempleman L, Sekiya T, et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567:530-534 pubmed publisher
  82. Melo Gonzalez F, Kammoun H, Evren E, Dutton E, Papadopoulou M, Bradford B, et al. Antigen-presenting ILC3 regulate T cell-dependent IgA responses to colonic mucosal bacteria. J Exp Med. 2019;216:728-742 pubmed publisher
  83. Michaels Y, Barnkob M, Barbosa H, Baeumler T, Thompson M, Andre V, et al. Precise tuning of gene expression levels in mammalian cells. Nat Commun. 2019;10:818 pubmed publisher
  84. Cox M, Duncan G, Lin G, Steinberg B, Yu L, Brenner D, et al. Choline acetyltransferase-expressing T cells are required to control chronic viral infection. Science. 2019;363:639-644 pubmed publisher
  85. Jin C, Lagoudas G, Zhao C, Bullman S, Bhutkar A, Hu B, et al. Commensal Microbiota Promote Lung Cancer Development via γδ T Cells. Cell. 2019;176:998-1013.e16 pubmed publisher
  86. Faliti C, Gualtierotti R, Rottoli E, Gerosa M, Perruzza L, Romagnani A, et al. P2X7 receptor restrains pathogenic Tfh cell generation in systemic lupus erythematosus. J Exp Med. 2019;216:317-336 pubmed publisher
  87. Wilson D, Hirosue S, Raczy M, Bonilla Ramirez L, Jeanbart L, Wang R, et al. Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity. Nat Mater. 2019;18:175-185 pubmed publisher
  88. McLaren J, Clement M, Marsden M, Miners K, Llewellyn Lacey S, Grant E, et al. IL-33 Augments Virus-Specific Memory T Cell Inflation and Potentiates the Efficacy of an Attenuated Cytomegalovirus-Based Vaccine. J Immunol. 2019;202:943-955 pubmed publisher
  89. Eldi P, Chaudhri G, Nutt S, Newsome T, Karupiah G. Viral Replicative Capacity, Antigen Availability via Hematogenous Spread, and High TFH:TFR Ratios Drive Induction of Potent Neutralizing Antibody Responses. J Virol. 2019;93: pubmed publisher
  90. Cornelissen L, Blanas A, van der Horst J, Kruijssen L, Zaal A, O Toole T, et al. Disruption of sialic acid metabolism drives tumor growth by augmenting CD8+ T cell apoptosis. Int J Cancer. 2019;144:2290-2302 pubmed publisher
  91. Karmaus P, Chen X, Lim S, Herrada A, Nguyen T, Xu B, et al. Metabolic heterogeneity underlies reciprocal fates of TH17 cell stemness and plasticity. Nature. 2019;565:101-105 pubmed publisher
  92. Obino D, Fetler L, Soza A, Malbec O, Saez J, Labarca M, et al. Galectin-8 Favors the Presentation of Surface-Tethered Antigens by Stabilizing the B Cell Immune Synapse. Cell Rep. 2018;25:3110-3122.e6 pubmed publisher
  93. Simula L, Pacella I, Colamatteo A, Procaccini C, Cancila V, Bordi M, et al. Drp1 Controls Effective T Cell Immune-Surveillance by Regulating T Cell Migration, Proliferation, and cMyc-Dependent Metabolic Reprogramming. Cell Rep. 2018;25:3059-3073.e10 pubmed publisher
  94. Ding L, Kim H, Wang Q, Kearns M, Jiang T, Ohlson C, et al. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018;25:2972-2980.e5 pubmed publisher
  95. Tan H, Jegaskanda S, Juno J, Esterbauer R, Wong J, Kelly H, et al. Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem. J Clin Invest. 2019;129:850-862 pubmed publisher
  96. Bouafia A, Lofek S, Bruneau J, Chentout L, Lamrini H, Trinquand A, et al. Loss of ARHGEF1 causes a human primary antibody deficiency. J Clin Invest. 2019;129:1047-1060 pubmed publisher
  97. Sorrelle N, Ganguly D, Dominguez A, Zhang Y, Huang H, Dahal L, et al. Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues. J Immunol. 2019;202:292-299 pubmed publisher
  98. Andre P, Denis C, Soulas C, Bourbon Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018;175:1731-1743.e13 pubmed publisher
  99. Theisen D, Davidson J, Briseño C, Gargaro M, Lauron E, Wang Q, et al. WDFY4 is required for cross-presentation in response to viral and tumor antigens. Science. 2018;362:694-699 pubmed publisher
  100. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity. 2018;49:264-274.e4 pubmed publisher
  101. Stathopoulou C, Gangaplara A, Mallett G, Flomerfelt F, Liniany L, Knight D, et al. PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells. Immunity. 2018;49:247-263.e7 pubmed publisher
  102. Zhang C, Wang C, Jiang M, Gu C, Xiao J, Chen X, et al. Act1 is a negative regulator in T and B cells via direct inhibition of STAT3. Nat Commun. 2018;9:2745 pubmed publisher
  103. Gisterå A, Klement M, Polyzos K, Mailer R, Duhlin A, Karlsson M, et al. LDL-Reactive T Cells Regulate Plasma Cholesterol Levels and Development of Atherosclerosis in Humanized Hypercholesterolemic Mice. Circulation. 2018;: pubmed publisher
  104. Du X, Wen J, Wang Y, Karmaus P, Khatamian A, Tan H, et al. Hippo/Mst signalling couples metabolic state and immune function of CD8α+ dendritic cells. Nature. 2018;558:141-145 pubmed publisher
  105. Crosby E, Wei J, Yang X, Lei G, Wang T, Liu C, et al. Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. Oncoimmunology. 2018;7:e1421891 pubmed publisher
  106. Anker J, Naseem A, Mok H, Schaeffer A, Abdulkadir S, Thumbikat P. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun. 2018;9:1591 pubmed publisher
  107. Gaddis D, Padgett L, Wu R, McSkimming C, Romines V, Taylor A, et al. Apolipoprotein AI prevents regulatory to follicular helper T cell switching during atherosclerosis. Nat Commun. 2018;9:1095 pubmed publisher
  108. Khan A, Carpenter B, Santos e Sousa P, Pospori C, Khorshed R, Griffin J, et al. Redirection to the bone marrow improves T cell persistence and antitumor functions. J Clin Invest. 2018;128:2010-2024 pubmed publisher
  109. Hailemichael Y, Woods A, Fu T, He Q, Nielsen M, Hasan F, et al. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest. 2018;128:1338-1354 pubmed publisher
  110. Cortes J, Ambesi Impiombato A, Couronné L, Quinn S, Kim C, da Silva Almeida A, et al. RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis. Cancer Cell. 2018;33:259-273.e7 pubmed publisher
  111. Ferdinand J, Richard A, Meylan F, Al Shamkhani A, Siegel R. Cleavage of TL1A Differentially Regulates Its Effects on Innate and Adaptive Immune Cells. J Immunol. 2018;200:1360-1369 pubmed publisher
  112. Nakashima H, Alayo Q, Penaloza MacMaster P, Freeman G, Kuchroo V, Reardon D, et al. Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep. 2018;8:208 pubmed publisher
  113. Barrow A, Edeling M, Trifonov V, Luo J, Goyal P, Bohl B, et al. Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor. Cell. 2018;172:534-548.e19 pubmed publisher
  114. Gaya M, Barral P, Burbage M, Aggarwal S, Montaner B, Warren Navia A, et al. Initiation of Antiviral B Cell Immunity Relies on Innate Signals from Spatially Positioned NKT Cells. Cell. 2018;172:517-533.e20 pubmed publisher
  115. Ibitokou S, Dillon B, Sinha M, Szczesny B, Delgadillo A, Reda Abdelrahman D, et al. Early Inhibition of Fatty Acid Synthesis Reduces Generation of Memory Precursor Effector T Cells in Chronic Infection. J Immunol. 2018;200:643-656 pubmed publisher
  116. Pedros C, Canonigo Balancio A, Kong K, Altman A. Requirement of Treg-intrinsic CTLA4/PKCη signaling pathway for suppressing tumor immunity. JCI Insight. 2017;2: pubmed publisher
  117. Shi B, Geng J, Wang Y, Wei H, Walters B, Li W, et al. Foxp1 Negatively Regulates T Follicular Helper Cell Differentiation and Germinal Center Responses by Controlling Cell Migration and CTLA-4. J Immunol. 2018;200:586-594 pubmed publisher
  118. Harly C, Cam M, Kaye J, Bhandoola A. Development and differentiation of early innate lymphoid progenitors. J Exp Med. 2018;215:249-262 pubmed publisher
  119. Singh M, Vianden C, Cantwell M, Dai Z, Xiao Z, Sharma M, et al. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat Commun. 2017;8:1447 pubmed publisher
  120. Kwak J, Laskowski J, Li H, McSharry M, Sippel T, Bullock B, et al. Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Res. 2018;78:143-156 pubmed publisher
  121. Mao A, Ishizuka I, Kasal D, Mandal M, Bendelac A. A shared Runx1-bound Zbtb16 enhancer directs innate and innate-like lymphoid lineage development. Nat Commun. 2017;8:863 pubmed publisher
  122. Yi W, Gupta S, Ricker E, Manni M, Jessberger R, Chinenov Y, et al. The mTORC1-4E-BP-eIF4E axis controls de novo Bcl6 protein synthesis in T cells and systemic autoimmunity. Nat Commun. 2017;8:254 pubmed publisher
  123. Kim S, Kwon J, Park J, Seo H, Jung K, Moon Y, et al. Achaete-scute complex homologue 2 accelerates the development of Sjögren's syndrome-like disease in the NOD/ShiLtJ mouse. Immunol Lett. 2017;190:26-33 pubmed publisher
  124. Billerbeck E, Wolfisberg R, Fahnøe U, Xiao J, Quirk C, Luna J, et al. Mouse models of acute and chronic hepacivirus infection. Science. 2017;357:204-208 pubmed publisher
  125. Chew V, Lai L, Pan L, Lim C, Li J, Ong R, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114:E5900-E5909 pubmed publisher
  126. Lynch A, Hawk W, Nylen E, Ober S, Autin P, Barber A. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma. Immunology. 2017;152:472-483 pubmed publisher
  127. Xie M, Koh B, Hollister K, Wu H, Sun J, Kaplan M, et al. Bcl6 promotes follicular helper T-cell differentiation and PD-1 expression in a Blimp1-independent manner in mice. Eur J Immunol. 2017;47:1136-1141 pubmed publisher
  128. Gordon S, Maute R, Dulken B, Hutter G, George B, McCracken M, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495-499 pubmed publisher
  129. Torcellan T, Hampton H, Bailey J, Tomura M, Brink R, Chtanova T. In vivo photolabeling of tumor-infiltrating cells reveals highly regulated egress of T-cell subsets from tumors. Proc Natl Acad Sci U S A. 2017;114:5677-5682 pubmed publisher
  130. Daley D, Mani V, Mohan N, Akkad N, Pandian G, Savadkar S, et al. NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. J Exp Med. 2017;214:1711-1724 pubmed publisher
  131. Lu P, Shih C, Qi H. Ephrin B1-mediated repulsion and signaling control germinal center T cell territoriality and function. Science. 2017;356: pubmed publisher
  132. Chien C, Yu H, Chen S, Chiang B. Characterization of c-Maf+Foxp3- Regulatory T Cells Induced by Repeated Stimulation of Antigen-Presenting B Cells. Sci Rep. 2017;7:46348 pubmed publisher
  133. Martinez Jimenez C, Eling N, Chen H, Vallejos C, Kolodziejczyk A, Connor F, et al. Aging increases cell-to-cell transcriptional variability upon immune stimulation. Science. 2017;355:1433-1436 pubmed publisher
  134. Sindhava V, Oropallo M, Moody K, Naradikian M, Higdon L, Zhou L, et al. A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens. J Clin Invest. 2017;127:1651-1663 pubmed publisher
  135. Ansa Addo E, Zhang Y, Yang Y, Hussey G, Howley B, Salem M, et al. Membrane-organizing protein moesin controls Treg differentiation and antitumor immunity via TGF-β signaling. J Clin Invest. 2017;127:1321-1337 pubmed publisher
  136. Pishesha N, Bilate A, Wibowo M, Huang N, Li Z, Deshycka R, et al. Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease. Proc Natl Acad Sci U S A. 2017;114:3157-3162 pubmed publisher
  137. Su S, Zou Z, Chen F, Ding N, Du J, Shao J, et al. CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. Oncoimmunology. 2017;6:e1249558 pubmed publisher
  138. Wu J, Sun L, Li H, Shen H, Zhai W, Yu Z, et al. Roles of programmed death protein 1/programmed death-ligand 1 in secondary brain injury after intracerebral hemorrhage in rats: selective modulation of microglia polarization to anti-inflammatory phenotype. J Neuroinflammation. 2017;14:36 pubmed publisher
  139. Zamarin D, Holmgaard R, Ricca J, Plitt T, Palese P, Sharma P, et al. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun. 2017;8:14340 pubmed publisher
  140. Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, et al. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood. 2017;129:2186-2197 pubmed publisher
  141. van Nieuwenhuijze A, Dooley J, Humblet Baron S, Sreenivasan J, Koenders M, Schlenner S, et al. Defective germinal center B-cell response and reduced arthritic pathology in microRNA-29a-deficient mice. Cell Mol Life Sci. 2017;74:2095-2106 pubmed publisher
  142. Blanquiceth Y, Rodríguez Perea A, Tabares Guevara J, Correa L, Sánchez M, Ramirez Pineda J, et al. Increase of Frequency and Modulation of Phenotype of Regulatory T Cells by Atorvastatin Is Associated with Decreased Lung Inflammatory Cell Infiltration in a Murine Model of Acute Allergic Asthma. Front Immunol. 2016;7:620 pubmed publisher
  143. Chen S, Cai C, Li Z, Liu G, Wang Y, Blonska M, et al. Dissection of SAP-dependent and SAP-independent SLAM family signaling in NKT cell development and humoral immunity. J Exp Med. 2017;214:475-489 pubmed publisher
  144. Kinosada H, Yasunaga J, Shimura K, Miyazato P, Onishi C, Iyoda T, et al. HTLV-1 bZIP Factor Enhances T-Cell Proliferation by Impeding the Suppressive Signaling of Co-inhibitory Receptors. PLoS Pathog. 2017;13:e1006120 pubmed publisher
  145. Morita K, Okamura T, Inoue M, Komai T, Teruya S, Iwasaki Y, et al. Egr2 and Egr3 in regulatory T cells cooperatively control systemic autoimmunity through Ltbp3-mediated TGF-β3 production. Proc Natl Acad Sci U S A. 2016;113:E8131-E8140 pubmed
  146. Li J, Shayan G, Avery L, Jie H, Gildener Leapman N, Schmitt N, et al. Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. Oncoimmunology. 2016;5:e1200778 pubmed
  147. Shirakawa K, Yan X, Shinmura K, Endo J, Kataoka M, Katsumata Y, et al. Obesity accelerates T cell senescence in murine visceral adipose tissue. J Clin Invest. 2016;126:4626-4639 pubmed publisher
  148. Hu Y, Kim J, He K, Wan Q, Kim J, Flach M, et al. Scramblase TMEM16F terminates T cell receptor signaling to restrict T cell exhaustion. J Exp Med. 2016;213:2759-2772 pubmed
  149. Kaewkangsadan V, Verma C, Eremin J, Cowley G, Ilyas M, Eremin O. Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. J Immunol Res. 2016;2016:4757405 pubmed
  150. Starobinets H, Ye J, Broz M, Barry K, Goldsmith J, Marsh T, et al. Antitumor adaptive immunity remains intact following inhibition of autophagy and antimalarial treatment. J Clin Invest. 2016;126:4417-4429 pubmed publisher
  151. Butcher M, Filipowicz A, Waseem T, McGary C, Crow K, Magilnick N, et al. Atherosclerosis-Driven Treg Plasticity Results in Formation of a Dysfunctional Subset of Plastic IFN?+ Th1/Tregs. Circ Res. 2016;119:1190-1203 pubmed publisher
  152. Li C, Lim S, Xia W, Lee H, Chan L, Kuo C, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632 pubmed publisher
  153. He R, Hou S, Liu C, Zhang A, Bai Q, Han M, et al. Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection. Nature. 2016;537:412-428 pubmed publisher
  154. Shi L, Fu T, Guan B, Chen J, Blando J, Allison J, et al. Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined ?-CTLA-4+?-PD-1 therapy. Nat Commun. 2016;7:12335 pubmed publisher
  155. Leong Y, Chen Y, Ong H, Wu D, Man K, Deléage C, et al. CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles. Nat Immunol. 2016;17:1187-96 pubmed publisher
  156. Pizzolla A, Oh D, Luong S, Prickett S, Henstridge D, Febbraio M, et al. High Fat Diet Inhibits Dendritic Cell and T Cell Response to Allergens but Does Not Impair Inhalational Respiratory Tolerance. PLoS ONE. 2016;11:e0160407 pubmed publisher
  157. Cheng H, Gaddis D, Wu R, McSkimming C, Haynes L, Taylor A, et al. Loss of ABCG1 influences regulatory T cell differentiation and atherosclerosis. J Clin Invest. 2016;126:3236-46 pubmed publisher
  158. Liu W, Kang S, Huang Z, Wu C, Jin H, Maine C, et al. A miR-155-Peli1-c-Rel pathway controls the generation and function of T follicular helper cells. J Exp Med. 2016;213:1901-19 pubmed publisher
  159. Yoshioka D, Kajiwara C, Ishii Y, Umeki K, Hiramatsu K, Kadota J, et al. Efficacy of ?-Lactam-plus-Macrolide Combination Therapy in a Mouse Model of Lethal Pneumococcal Pneumonia. Antimicrob Agents Chemother. 2016;60:6146-54 pubmed publisher
  160. Seifert A, Zeng S, Zhang J, Kim T, Cohen N, Beckman M, et al. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res. 2017;23:454-465 pubmed publisher
  161. Saha A, O Connor R, Thangavelu G, Lovitch S, Dandamudi D, Wilson C, et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016;126:2642-60 pubmed publisher
  162. Jackson S, Jacobs H, Arkatkar T, Dam E, Scharping N, Kolhatkar N, et al. B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. J Exp Med. 2016;213:733-50 pubmed publisher
  163. Friedman K, Brodsky A, Lu S, Wood S, Gill A, Lombardo K, et al. Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. Mod Pathol. 2016;29:528-41 pubmed publisher
  164. Chen W, Wang J, Jia L, Liu J, Tian Y. Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan. Cell Death Dis. 2016;7:e2115 pubmed publisher
  165. Kim J, Choi Y, Lee B, Song M, Ban C, Kim J, et al. Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells. J Allergy Clin Immunol. 2016;137:1466-1476.e3 pubmed publisher
  166. Tubo N, Fife B, Pagán A, Kotov D, Goldberg M, Jenkins M. Most microbe-specific naïve CD4? T cells produce memory cells during infection. Science. 2016;351:511-4 pubmed publisher
  167. Aloulou M, Carr E, Gador M, Bignon A, Liblau R, Fazilleau N, et al. Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells. Nat Commun. 2016;7:10579 pubmed publisher
  168. Chandrasekaran U, Yi W, Gupta S, Weng C, Giannopoulou E, Chinenov Y, et al. Regulation of Effector Treg Cells in Murine Lupus. Arthritis Rheumatol. 2016;68:1454-66 pubmed publisher
  169. McDonald P, Read K, Baker C, Anderson A, Powell M, Ballesteros Tato A, et al. IL-7 signalling represses Bcl-6 and the TFH gene program. Nat Commun. 2016;7:10285 pubmed publisher
  170. Yasuma K, Yasunaga J, Takemoto K, Sugata K, Mitobe Y, Takenouchi N, et al. HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT). PLoS Pathog. 2016;12:e1005372 pubmed publisher
  171. Everts B, Tussiwand R, Dreesen L, Fairfax K, Huang S, Smith A, et al. Migratory CD103+ dendritic cells suppress helminth-driven type 2 immunity through constitutive expression of IL-12. J Exp Med. 2016;213:35-51 pubmed publisher
  172. Black L, Srivastava R, Schoeb T, Moore R, Barnes S, KABAROWSKI J. Cholesterol-Independent Suppression of Lymphocyte Activation, Autoimmunity, and Glomerulonephritis by Apolipoprotein A-I in Normocholesterolemic Lupus-Prone Mice. J Immunol. 2015;195:4685-98 pubmed publisher
  173. Laurent C, Charmpi K, Gravelle P, Tosolini M, Franchet C, Ysebaert L, et al. Several immune escape patterns in non-Hodgkin's lymphomas. Oncoimmunology. 2015;4:e1026530 pubmed
  174. Manlove L, Berquam Vrieze K, Pauken K, Williams R, Jenkins M, Farrar M. Adaptive Immunity to Leukemia Is Inhibited by Cross-Reactive Induced Regulatory T Cells. J Immunol. 2015;195:4028-37 pubmed publisher
  175. Andersson K, Brisslert M, Cavallini N, Svensson M, Welin A, Erlandsson M, et al. Survivin co-ordinates formation of follicular T-cells acting in synergy with Bcl-6. Oncotarget. 2015;6:20043-57 pubmed
  176. Schmidt L, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch J, et al. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS ONE. 2015;10:e0136023 pubmed publisher
  177. Choi Y, Gullicksrud J, Xing S, Zeng Z, Shan Q, Li F, et al. LEF-1 and TCF-1 orchestrate T(FH) differentiation by regulating differentiation circuits upstream of the transcriptional repressor Bcl6. Nat Immunol. 2015;16:980-90 pubmed publisher
  178. Ngiow S, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res. 2015;75:3800-11 pubmed publisher
  179. Kamachi F, Isshiki T, Harada N, Akiba H, Miyake S. ICOS promotes group 2 innate lymphoid cell activation in lungs. Biochem Biophys Res Commun. 2015;463:739-45 pubmed publisher
  180. Imai Y, Ayithan N, Wu X, Yuan Y, Wang L, Hwang S. Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells. J Immunol. 2015;195:421-5 pubmed publisher
  181. Shao L, Lie A, Zhang Y, Wong C, Kwong Y. Aberrant germinal center formation, follicular T-helper cells, and germinal center B-cells were involved in chronic graft-versus-host disease. Ann Hematol. 2015;94:1493-504 pubmed publisher
  182. Moguche A, Shafiani S, Clemons C, Larson R, Dinh C, Higdon L, et al. ICOS and Bcl6-dependent pathways maintain a CD4 T cell population with memory-like properties during tuberculosis. J Exp Med. 2015;212:715-28 pubmed publisher
  183. Dahlgren M, Gustafsson Hedberg T, Livingston M, Cucak H, Alsén S, Yrlid U, et al. T follicular helper, but not Th1, cell differentiation in the absence of conventional dendritic cells. J Immunol. 2015;194:5187-99 pubmed publisher
  184. Rouhani S, Eccles J, Riccardi P, Peske J, Tewalt E, Cohen J, et al. Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction. Nat Commun. 2015;6:6771 pubmed publisher
  185. Li C, Li W, Xiao J, Jiao S, Teng F, Xue S, et al. ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy. EMBO Mol Med. 2015;7:754-69 pubmed publisher
  186. Kim Y, Lim H, Jung H, Wetsel R, Chung Y. Regulation of autoimmune germinal center reactions in lupus-prone BXD2 mice by follicular helper T cells. PLoS ONE. 2015;10:e0120294 pubmed publisher
  187. Pratama A, Srivastava M, Williams N, Papa I, Lee S, Dinh X, et al. MicroRNA-146a regulates ICOS-ICOSL signalling to limit accumulation of T follicular helper cells and germinal centres. Nat Commun. 2015;6:6436 pubmed publisher
  188. Yang Z, Grote D, Ziesmer S, Xiu B, Novak A, Ansell S. PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival. Blood Cancer J. 2015;5:e281 pubmed publisher
  189. Okamura T, Sumitomo S, Morita K, Iwasaki Y, Inoue M, Nakachi S, et al. TGF-β3-expressing CD4+CD25(-)LAG3+ regulatory T cells control humoral immune responses. Nat Commun. 2015;6:6329 pubmed publisher
  190. Jing W, Gershan J, Weber J, Tlomak D, McOlash L, Sabatos Peyton C, et al. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer. 2015;3:2 pubmed publisher
  191. Clouthier D, Zhou A, Wortzman M, Luft O, Levy G, Watts T. GITR intrinsically sustains early type 1 and late follicular helper CD4 T cell accumulation to control a chronic viral infection. PLoS Pathog. 2015;11:e1004517 pubmed publisher
  192. Shrestha S, Yang K, Guy C, Vogel P, Neale G, Chi H. Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. Nat Immunol. 2015;16:178-87 pubmed publisher
  193. Guo X, Tanaka Y, Kondo M. Thymic precursors of TCRαβ(+)CD8αα(+) intraepithelial lymphocytes are negative for CD103. Immunol Lett. 2015;163:40-8 pubmed publisher
  194. Buchan S, Manzo T, Flutter B, Rogel A, Edwards N, Zhang L, et al. OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence. J Immunol. 2015;194:125-133 pubmed publisher
  195. Gao F, Wang W. MicroRNA-96 promotes the proliferation of colorectal cancer cells and targets tumor protein p53 inducible nuclear protein 1, forkhead box protein O1 (FOXO1) and FOXO3a. Mol Med Rep. 2015;11:1200-6 pubmed publisher
  196. Naik E, Webster J, DeVoss J, Liu J, Suriben R, Dixit V. Regulation of proximal T cell receptor signaling and tolerance induction by deubiquitinase Usp9X. J Exp Med. 2014;211:1947-55 pubmed publisher
  197. Dai M, Yip Y, Hellstrom I, Hellstrom K. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res. 2015;21:1127-38 pubmed publisher
  198. Penaloza MacMaster P, Kamphorst A, Wieland A, Araki K, Iyer S, West E, et al. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med. 2014;211:1905-18 pubmed publisher
  199. Zhu Y, Knolhoff B, Meyer M, Nywening T, West B, Luo J, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74:5057-69 pubmed publisher
  200. Vogelzang A, Perdomo C, Zedler U, Kuhlmann S, Hurwitz R, Gengenbacher M, et al. Central memory CD4+ T cells are responsible for the recombinant Bacillus Calmette-Guérin ?ureC::hly vaccine's superior protection against tuberculosis. J Infect Dis. 2014;210:1928-37 pubmed publisher
  201. León B, Bradley J, Lund F, Randall T, Ballesteros Tato A. FoxP3+ regulatory T cells promote influenza-specific Tfh responses by controlling IL-2 availability. Nat Commun. 2014;5:3495 pubmed publisher
  202. Barsoum I, Smallwood C, Siemens D, Graham C. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014;74:665-74 pubmed publisher
  203. Bodhankar S, Chen Y, Vandenbark A, Murphy S, Offner H. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1. J Neuroinflammation. 2013;10:111 pubmed publisher
  204. Van Der Werf N, Redpath S, Azuma M, Yagita H, Taylor M. Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection. PLoS Pathog. 2013;9:e1003215 pubmed publisher
  205. Wollenberg I, Agua Doce A, Hernandez A, Almeida C, Oliveira V, Faro J, et al. Regulation of the germinal center reaction by Foxp3+ follicular regulatory T cells. J Immunol. 2011;187:4553-60 pubmed publisher
  206. Tousif S, Singh Y, Prasad D, Sharma P, Van Kaer L, Das G. T cells from Programmed Death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection. PLoS ONE. 2011;6:e19864 pubmed publisher
  207. Nakae S, Iwakura Y, Suto H, Galli S. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol. 2007;81:1258-68 pubmed
  208. Kuipers H, Muskens F, Willart M, Hijdra D, van Assema F, Coyle A, et al. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. Eur J Immunol. 2006;36:2472-82 pubmed
  209. Schoop R, Wahl P, Le Hir M, Heemann U, Wang M, Wuthrich R. Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells. Nephrol Dial Transplant. 2004;19:2713-20 pubmed